Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment

Introduction: Treatment options for neuroendocrine tumors (NETs) are rarely curative, as NETs frequently show resistance to medical therapy. The use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signaling. In this context, the an...

Full description

Bibliographic Details
Main Authors: Eleonora Vitali, Ilena Boemi, Giulia Tarantola, Sara Piccini, Alessandro Zerbi, Giulia Veronesi, Roberto Baldelli, Gherardo Mazziotti, Valeria Smiroldo, Elisabetta Lavezzi, Anna Spada, Giovanna Mantovani, Andrea G. Lania
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
metformin
everolimus
neuroendocrine tumors
resistance
Online Access:https://www.mdpi.com/2072-6694/12/8/2143

Internet

https://www.mdpi.com/2072-6694/12/8/2143

Similar Items